JPH07502734A - 血液損失を減少する方法および組成物 - Google Patents
血液損失を減少する方法および組成物Info
- Publication number
- JPH07502734A JPH07502734A JP51191893A JP51191893A JPH07502734A JP H07502734 A JPH07502734 A JP H07502734A JP 51191893 A JP51191893 A JP 51191893A JP 51191893 A JP51191893 A JP 51191893A JP H07502734 A JPH07502734 A JP H07502734A
- Authority
- JP
- Japan
- Prior art keywords
- factor xiii
- factor
- surgery
- administered
- blood loss
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (14)
- 1.手術を受ける患者における術中血液損失の減少のための医薬薬組成物の製造 に対する因子XIIIの使用。
- 2.手術を受ける患者における術中血液損失を減少させるための医薬組成物であ って、生物学的に適合性のビヒクル中に因子XIIIを含んでなる、前記医薬組 成物。
- 3.因子XIIIが因子XIIIa2ダイマーである、請求の範囲第2項記載の 組成物。
- 4.因子XIIIが組換え体因子XIIIである、請求の範囲第2項記載の組成 物。
- 5.手術を受ける患者における術中血液損失を減少する方法であって、生物学的 に適合性のビヒクル中の有効量の因子XIIIを患者に投与することを含んでな る、前記方法。
- 6.因子XIIIを手術前注射薬として投与する、請求の範囲第5項記載の方法 。
- 7.因子XIIIを手術前1日以内に投与する、請求の範囲第6項記載の方法。
- 8.因子XIIIを患者の体重1kg当たり0.1〜1.0mgの用量で投与す る、請求の範囲第5項記載の方法。
- 9.因子XIIIを患者の体重1kg当たり0.15〜0.4mgの用量で投与 する、請求の範囲第5項記載の方法。
- 10.因子XIIIが因子XIIIa2ダイマーである、請求の範囲第5項記載 の方法。
- 11.因子XIIIが組換え体因子XIIIである、請求の範囲第5項記載の方 法。
- 12.更に患者にアプロチニンを投与することを含んでなる、請求の範囲第5項 記載の方法。
- 13.アプロチニンを、2×106KIU〜8×106KIUの用量で投与する 、請求の範囲第12項記載の方法。
- 14.手術が胸の手術である、請求の範囲第2項記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US81544391A | 1991-12-31 | 1991-12-31 | |
US815,443 | 1991-12-31 | ||
PCT/US1992/011241 WO1993012813A1 (en) | 1991-12-31 | 1992-12-28 | Methods and compositions for reducing blood loss |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH07502734A true JPH07502734A (ja) | 1995-03-23 |
Family
ID=25217802
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51191893A Pending JPH07502734A (ja) | 1991-12-31 | 1992-12-28 | 血液損失を減少する方法および組成物 |
Country Status (8)
Country | Link |
---|---|
US (1) | US5607917A (ja) |
EP (1) | EP0624095B2 (ja) |
JP (1) | JPH07502734A (ja) |
AT (1) | ATE171071T1 (ja) |
AU (1) | AU3423493A (ja) |
CA (1) | CA2127107C (ja) |
DE (1) | DE69227042T3 (ja) |
WO (1) | WO1993012813A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8383776B2 (en) | 2004-08-27 | 2013-02-26 | Novo Nordisk Health Care Ag | Purification of factor XIII polypeptides from biological materials |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5525335A (en) * | 1992-04-21 | 1996-06-11 | Ajinomoto Co., Inc. | Wound healing agent |
BR0110659A (pt) * | 2000-05-10 | 2003-02-11 | Novo Nordisk As | Composição farmacêutica, kit, uso de um fator viia em combinação com um fator, xiii, e, métodos para intensificação da formação de coágulo de fibrina em um indivìduo e para tratar de episódios de hemorragia em um indivìduo |
WO2002036573A2 (en) | 2000-10-31 | 2002-05-10 | Rensselaer Polytechnic Institute | 8- substituted-2, 6-methano-3-benzazocines and 3-substituted morphinanes as opioid receptor binding agents |
JP2004537505A (ja) * | 2001-02-21 | 2004-12-16 | ザイモジェネティクス,インコーポレイティド | 血小板疾患を処理するための血液凝固第viii因子 |
US7008926B2 (en) * | 2001-02-22 | 2006-03-07 | Zymogenetics Inc. | Blood coagulation factor XIII for treating platelet disorders |
WO2005115442A1 (en) * | 2004-05-25 | 2005-12-08 | Novo Nordisk Health Care Ag | Use of coagulation factor xiii for treatment of post surgical bleedings |
AU2005308830B2 (en) | 2004-11-23 | 2012-01-19 | Zymogenetics, Inc. | Purification of recombinant human factor XIII |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3931399A (en) † | 1970-12-22 | 1976-01-06 | Behringwerke Aktiengesellschaft | Process for isolating a fibrin-stabilizing factor |
GB1575343A (en) * | 1977-05-10 | 1980-09-17 | Ici Ltd | Method for preparing liposome compositions containing biologically active compounds |
US4235877A (en) * | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
EP0049611B2 (en) * | 1980-10-02 | 1993-12-08 | Hooper Trading Co. N.V. | A T-cell growth factor, and a process of producing the same |
US4464355A (en) * | 1981-03-26 | 1984-08-07 | Hooper Trading Co. | Serum-free and mitogen-free T-cell growth factor and process for making same |
US4684625A (en) * | 1982-07-08 | 1987-08-04 | Syntex (U.S.A.) Inc. | Method for enhancing the anti-infective activity of muramyldipeptide derivatives |
US4522811A (en) * | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4683199A (en) * | 1983-01-31 | 1987-07-28 | Sloan-Kettering Institute For Cancer Research | Interleukin-2 dependent cytotoxic T-cell clones |
US4588578A (en) * | 1983-08-08 | 1986-05-13 | The Liposome Company, Inc. | Lipid vesicles prepared in a monophase |
US4518584A (en) * | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
CA1237671A (en) * | 1983-08-01 | 1988-06-07 | Michael W. Fountain | Enhancement of pharmaceutical activity |
US4565696A (en) * | 1983-08-03 | 1986-01-21 | The Regents Of The University Of California | Production of immunogens by antigen conjugation to liposomes |
US4599227A (en) * | 1983-11-07 | 1986-07-08 | Wisconsin Alumni Research Foundation | Injectable pharmaceutical preparation for the induction of multiple follicular growth |
US4708861A (en) * | 1984-02-15 | 1987-11-24 | The Liposome Company, Inc. | Liposome-gel compositions |
GB8405555D0 (en) * | 1984-03-02 | 1984-04-04 | Rees A D M | Macrophage activating factors |
US4604377A (en) * | 1984-03-28 | 1986-08-05 | Cetus Corporation | Pharmaceutical compositions of microbially produced interleukin-2 |
US4636463A (en) * | 1984-04-05 | 1987-01-13 | Scripps Clinic And Research Foundation | Antibodies to human interleukin-2 induced by synthetic polypeptides |
BE902089A (fr) * | 1984-04-09 | 1985-10-02 | Sandoz Sa | Perfectionnements a la therapie par l'interleukine. |
FR2562421B1 (fr) * | 1984-04-09 | 1989-02-17 | Sandoz Sa | Perfectionnements a la therapie par l'interleukine |
US4721612A (en) * | 1984-04-12 | 1988-01-26 | The Liposome Company, Inc. | Steroidal liposomes |
EP0172007B1 (en) * | 1984-08-10 | 1991-05-22 | Syntex (U.S.A.) Inc. | Stable liposomes with aqueous-soluble medicaments and methods for their preparation |
CA1260393A (en) * | 1984-10-16 | 1989-09-26 | Lajos Tarcsay | Liposomes of synthetic lipids |
US4689222A (en) * | 1985-01-18 | 1987-08-25 | Mcmichael John | Methods and materials for alleviation of pain symptoms of malignant neoplasia |
CA1256372A (en) * | 1985-04-11 | 1989-06-27 | Koichiro Miyazima | Process for producing liposome composition |
US4663161A (en) * | 1985-04-22 | 1987-05-05 | Mannino Raphael J | Liposome methods and compositions |
EP0203403B1 (en) * | 1985-05-01 | 1992-10-28 | Asahi Kasei Kogyo Kabushiki Kaisha | A cloned t cell capable of recognizing tumors and a t cell antigen receptor |
US4774085A (en) * | 1985-07-09 | 1988-09-27 | 501 Board of Regents, Univ. of Texas | Pharmaceutical administration systems containing a mixture of immunomodulators |
US4690915A (en) * | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
ES2039203T3 (es) * | 1985-11-22 | 1993-09-16 | Takeda Chemical Industries, Ltd. | Composicion de liposomas. |
WO1987004592A1 (en) * | 1986-02-10 | 1987-08-13 | Liposome Technology, Inc. | Controlled-release liposome delivery system |
JPH0751496B2 (ja) * | 1986-04-02 | 1995-06-05 | 武田薬品工業株式会社 | リポソ−ムの製造法 |
WO1988000970A2 (en) * | 1986-08-08 | 1988-02-11 | Regents Of The University Of Minnesota | Method of culturing leukocytes |
US4752425A (en) * | 1986-09-18 | 1988-06-21 | Liposome Technology, Inc. | High-encapsulation liposome processing method |
US4781871A (en) * | 1986-09-18 | 1988-11-01 | Liposome Technology, Inc. | High-concentration liposome processing method |
EP0268772B1 (en) * | 1986-09-19 | 1995-04-26 | ZymoGenetics, Inc. | Expression of biologically active factor XIII |
US5017556A (en) * | 1986-11-04 | 1991-05-21 | Genentech, Inc. | Treatment of bleeding disorders using lipid-free tissue factor protein |
JP2660341B2 (ja) * | 1986-12-04 | 1997-10-08 | 武田薬品工業株式会社 | リポソーム製剤およびその製造法 |
JPS63196520A (ja) * | 1987-02-09 | 1988-08-15 | Hoechst Japan Kk | 潰瘍性大腸炎治療剤 |
US4808151A (en) * | 1987-04-27 | 1989-02-28 | E. I. Du Pont De Nemours And Company | Simplified method for the preparation of human lymphokine activated killer cells |
EP0390849B1 (en) * | 1987-12-03 | 1993-01-07 | The Liposome Company, Inc. | Methyl cellulose pharmaceutical composition |
AU2925789A (en) * | 1987-12-17 | 1989-07-19 | Browning's Clinical Pathology Services Limited | Lymphokine activation of cells for adoptive immunotherapy, e.g. of hiv infection |
FR2624741B1 (fr) * | 1987-12-21 | 1991-06-28 | Pasteur Institut | Compositions a base d'une combinaison de liposomes et de lymphokine presentant des proprietes immunostimulantes et leurs applications en medecine humaine et veterinaire |
JPH01216939A (ja) * | 1988-02-24 | 1989-08-30 | Hoechst Japan Kk | 末熟児頭蓋内出血阻止剤 |
EP0409901A4 (en) * | 1988-04-15 | 1991-10-30 | Research Corporation Technologies, Inc | Lak cell cytotoxin |
DE68913003T2 (de) * | 1988-05-16 | 1994-06-09 | Vestar Inc | An hormone gekoppelte liposome. |
US5204447A (en) * | 1988-11-14 | 1993-04-20 | Zymogenetics, Inc. | Purification of factor xiii |
US5047406A (en) * | 1989-12-06 | 1991-09-10 | Warner-Lambert Co. | Substituted cyclohexanols as central nervous system agents |
-
1992
- 1992-12-28 JP JP51191893A patent/JPH07502734A/ja active Pending
- 1992-12-28 EP EP93902779A patent/EP0624095B2/en not_active Expired - Lifetime
- 1992-12-28 DE DE69227042T patent/DE69227042T3/de not_active Expired - Lifetime
- 1992-12-28 AT AT93902779T patent/ATE171071T1/de not_active IP Right Cessation
- 1992-12-28 CA CA002127107A patent/CA2127107C/en not_active Expired - Lifetime
- 1992-12-28 AU AU34234/93A patent/AU3423493A/en not_active Abandoned
- 1992-12-28 WO PCT/US1992/011241 patent/WO1993012813A1/en active IP Right Grant
-
1995
- 1995-05-31 US US08/456,018 patent/US5607917A/en not_active Expired - Lifetime
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8383776B2 (en) | 2004-08-27 | 2013-02-26 | Novo Nordisk Health Care Ag | Purification of factor XIII polypeptides from biological materials |
Also Published As
Publication number | Publication date |
---|---|
EP0624095A1 (en) | 1994-11-17 |
CA2127107C (en) | 2007-06-19 |
ATE171071T1 (de) | 1998-10-15 |
DE69227042T2 (de) | 1999-05-27 |
WO1993012813A1 (en) | 1993-07-08 |
US5607917A (en) | 1997-03-04 |
CA2127107A1 (en) | 1993-07-08 |
DE69227042D1 (de) | 1998-10-22 |
DE69227042T3 (de) | 2006-07-27 |
EP0624095B1 (en) | 1998-09-16 |
AU3423493A (en) | 1993-07-28 |
EP0624095B2 (en) | 2005-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ERSLEV | Erythropoietic function in uremic rabbits | |
Lessard et al. | Isoflurane-induced hypotension in orthognathic surgery | |
JPS6259222A (ja) | 繊維素溶解を低下させる溶液およびその溶液の調製に使用される溶質 | |
JP3012319B2 (ja) | 脳及び筋肉組織傷害による浮腫の治療剤 | |
NIEUWENHUIS et al. | 1-Desamino-8-D-arginine vasopressin (desmopressin) shortens the bleeding time in storage pool deficiency | |
JPH07502734A (ja) | 血液損失を減少する方法および組成物 | |
TW201425332A (zh) | 抗凝血酶用於體外膜氧合之用途 | |
Baez et al. | Role of the neurohypophysis in ferritin-induced antidiuresis | |
PT89802B (pt) | Processo para a preparacao de uma composicao farmaceutica, contendo o factor xiii de coagulacao do sangue humano, para a prevencao da hemorragia intraventricular em criancas permaturas | |
CN105431165A (zh) | 用于治疗心肺手术后的术后并发症的组合物和方法 | |
CAMPBELL et al. | Plasma thromboplastin antecedent (PTA) deficiency | |
Olsen | Intracranial surgery in hemophiliacs: report of a case and review of the literature | |
US20200038489A1 (en) | Novel Use of Von Willebrand Factor | |
JP3742675B2 (ja) | 虚血−再灌流障害の予防および治療薬 | |
JPH0684965B2 (ja) | 血液製剤中の不適合反応原因物質の試験法 | |
SK92194A3 (en) | Pharmaceutical agent method of its preparing and using | |
JP2004231664A (ja) | 出血を阻止するため局所に塗布する第xiii因子の用途 | |
JPH07196650A (ja) | 平滑筋細胞増殖抑制作用を有するアルガトロバン製剤 | |
JPS63132843A (ja) | 抗炎症剤 | |
RU2816883C1 (ru) | Способ профилактики геморрагических осложнений у пациенток с болезнью Виллебранда при проведении экстракорпорального оплодотворения | |
Farman | 5 ANAESTHESIA FOR TRANSPLANT SURGERY | |
JPH08231416A (ja) | 血栓症治療剤 | |
JP3884064B6 (ja) | 出血を阻止するため局所に塗布する第▲xiii▼因子の用途 | |
Tolleth et al. | Regional isolation perfusion in the treatment of advanced malignant disease | |
OKAMOTO et al. | The Depressor Principle in the Kidney of the New-born Rat: I. SOME BIOLOGICAL AND PHYSICOCHEMICAL PROPERTIES OF THE KIDNEY EXTRACT OF THE NEW-BORN RAT |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20031205 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20040126 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040224 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20050118 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050518 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20050616 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20050915 |